Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-SPECT CVT
2015-004412-38Phase 3Completed
- Sponsor
- Unilfarma
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cerebral sinovenous thrombosis (CSVT) comparing Dabigatran etexilate with Warfarin (2 arms). Primary endpoint: Composite of major bleeding and venous thrombotic events. Started Aug 2016; status: completed.
02
Drugs
dabigatranwarfarin
03
Conditions
cerebral sinovenous thrombosis (CSVT)
Beyond the preview
Go deeper on 2015-004412-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004412-38.